Innoviva Number of Employees 2010-2025 | INVA

Innoviva number of employees from 2010 to 2025. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
Innoviva Annual Employee Count
2024 127
2023 112
2022 101
2021 5
2020 5
2019 6
2018 6
2017 12
2016 14
2015 13
2014 10
2013 241
2012 226
2011 222
2010 193
2009 194
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.307B $0.359B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $730.363B 56.01
Johnson & Johnson (JNJ) United States $364.087B 15.06
AbbVie (ABBV) United States $324.594B 17.89
Roche Holding AG (RHHBY) Switzerland $255.373B 0.00
Novartis AG (NVS) Switzerland $248.252B 14.18
Merck (MRK) United States $201.284B 10.29
Pfizer (PFE) United States $136.619B 7.49
Sanofi (SNY) France $118.160B 11.64
Bayer (BAYRY) Germany $29.984B 6.10
Novo Nordisk (NVO) Denmark $0.000B 20.63